EGFR and non-small cell lung carcinoma: Given the emerging evidence for combined strategies involving third‐generation EGFR‐TKI agents and their potential benefit for the Asian population, where the disease burden is high, it is crucial to understand current diagnostic and treatment patterns for advanced EGFRm NSCLC from an Asian perspective.